WHO ICTRP trial
Investigating the in vivo bioequivalence of Celecoxib 100 mg tablet
IRCT20210519051345N15 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20210519051345N15 |
|---|---|
| Public title | Investigating the in vivo bioequivalence of Celecoxib 100 mg tablet |
| Scientific title | Fasted-state in vivo bioequivalence study of Celecoxib 100 mg tablet manufactured by Farnoush Daru Teb Co. compared with innovator product |
| Primary sponsor | Tabriz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | In the present study, the products will be administered to healthy volunteers.. |
| Interventions | Intervention 1: Intervention group: Intervention group will receive a single test drug product. Blood samples will be collected for48 hours at the mentioned times after drug administration and the concentration of drug in blood samples will… |
| Registration date | Aug 17, 2022 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: